Alexandra Hernandez - 07 Jul 2022 Form 3 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Sr Director Finance/Controller
Signature
/s/ Alexandra Hernandez
Issuer symbol
LCTX
Transactions as of
07 Jul 2022
Net transactions value
$0
Form type
3
Filing time
08 Jul 2022, 18:25:35 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LCTX Employee Stock Option (Right to Buy) 07 Jul 2022 Common Shares 100,000 $0.9000 Direct F1
holding LCTX Employee Stock Option (Right to Buy) 07 Jul 2022 Common Shares 29,192 $0.6919 Direct F2
holding LCTX Employee Stock Option (Right to Buy) 07 Jul 2022 Common Shares 42,700 $2.43 Direct F3
holding LCTX Employee Stock Option (Right to Buy) 07 Jul 2022 Common Shares 48,000 $1.40 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One quarter of the options vested on September 1, 2020 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.
F2 One quarter of the options vested on March 17, 2021 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.
F3 One quarter of the options vested on March 15, 2022 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.
F4 One quarter of the options will vest on March 10, 2023 and the remaining will vest in 36 equal monthly installments thereafter upon the completion of each month of continuous employment.